Lakefront Biotherapeutics

Stage 1 · Basing · week 2

As of Oct 22, 2026, Lakefront Biotherapeutics is in Stage 1, the basing phase, now in week 2 (since Oct 13, 2026). It closed at $31.40, 9.4% below its 52-week high and above its 200-day average, which is falling.

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. More about the company

$31.40

+1.78% today

$2.1B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is LKFT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 26w

S4 21w

S2 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 14w → S1 7w → S2 5w → S3 1w → S4 26w → S1 11w → S4 21w → S1 9w → S2 21w → S3 9w → S2 9w → S3 3w → S4 12w → S1 9w → S4 4w → S1 1w current

Total tracked: 164 weeks across 17 stage runs.

LKFT among Biotechnology188th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…188	LKFTLakefront Biotherapeutics	Stage 1 · wk 2	54	+2.2%

vs 52W High

-9.4%

$26.08 lo$34.64 hi

9.4% below 52W high, pullback range

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 2

1w13w26w

Week 2, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

4.8%

200 DMA: $29.96 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

1.05x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↗

Short-term trend rising gently

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+2.2%

+12.8%

+9.5%

YTD

-4.8%

-0.1%

Scan Membership

Breakout Watch

Latest: 2025-06-18

9 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 2 · Vol 1.05x

2026-10-21S1

Wk 2 · Vol 0.41x

2026-10-20S1

Wk 2 · Vol 0.99x

2026-10-19S1

Wk 1 · Vol 0.47x

2026-10-16S1

Wk 1 · Vol 0.84x

2026-10-15S1

Wk 1 · Vol 0.75x

2026-10-14S1

Wk 1 · Vol 0.75x

2026-10-13S14→1

Wk 1 · Vol 0.58x

2026-10-12S4

Wk 5 · Vol 0.73x

2026-10-09S4

Wk 4 · Vol 0.70x

2026-10-08S4

Wk 4 · Vol 1.70x

2026-10-07S4

Wk 4 · Vol 1.24x

Moving averages & range

50 DMA

$29.03

200 DMA

$29.96

52W High

$34.64

52W Low

$26.08

5D Low

$29.79

Resistance levels (recent highs)

20d High

$31.40

60d High

$31.40

120d High

$31.40

250d High

$34.64

Next resistance

+10.3%

to 250d High

P/E (TTM)

3.0

Forward -26.4

ROE

+20.1%

Profit margin +60.2%

Dividend Yield

0.00%

P/B 11.3

Lakefront Biotherapeutics: quick answers

What stage is Lakefront Biotherapeutics in?

As of Oct 22, 2026, Lakefront Biotherapeutics (LKFT) is in Stage 1, the basing phase. It entered Stage 1 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Lakefront Biotherapeutics in an uptrend?

Not yet. Lakefront Biotherapeutics is in Stage 1, a base that can come before an uptrend. It trades 4.8% above its 200-day average, which is falling.

How far is Lakefront Biotherapeutics from its 52-week high?

Lakefront Biotherapeutics closed at $31.40 on Oct 22, 2026, 9.4% below its 52-week high of $34.64. Its 52-week low is $26.08.

How has Lakefront Biotherapeutics performed over the past year?

As of Oct 22, 2026, Lakefront Biotherapeutics is down 0.1% over the past year and down 4.8% so far in 2026.

Which sector and industry is Lakefront Biotherapeutics in?

Lakefront Biotherapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.